The Diabetic Retinopathy Screening, Prevention and Control Program
Condition(s) studied
Study summary
The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.
Eligibility
Primary outcome measure(s)
- Diabetic retinopathy — through study completion, up to 20 years
diabetic retinopathy - Referable diabetic retinopathy — through study completion, up to 20 years
Referable diabetic retinopathy - Vision threatening diabetic retinopathy — through study completion, up to 20 years
Vision threatening diabetic retinopathy - Diabetic macular edema — through study completion, up to 20 years
Diabetic macular edema
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Ruijin hospital, Shanghai Jiao-Tong University School of Medicine | Shanghai | Shanghai Municipality | Recruiting |
| Shanghai Jiao-Tong University School of Medicine | Shanghai | China | Recruiting |
More Shanghai Jiao Tong University School of Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04240652 on ClinicalTrials.gov ↗ ← All trials in China